Eiger Biopharmaceuticals (EIGR) Receives a Buy from Ladenburg Thalmann & Co.

By Carrie Williams

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Eiger Biopharmaceuticals (EIGRResearch Report), with a price target of $28.00. The company’s shares closed last Monday at $10.97.

According to TipRanks.com, Higgins ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -15.5% and a 27.4% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Armata Pharmaceuticals, and Rhythm Pharmaceuticals.

Eiger Biopharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $31.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $15.33 and a one-year low of $8.40. Currently, Eiger Biopharmaceuticals has an average volume of 112.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Eiger BioPharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of well-characterized drugs for life-threatening, rare and ultra-rare diseases with high unmet medical needs and no approved therapies.